1. Scrip
  2. >>Business
  3. >>Deals

Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts

Peanut Allergy Therapy Has Been Commercial Flop

 
• By Kevin Grogan

Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.

Peanut allergy concept
• Source: Shutterstock

Three years after inking a $2.6bn deal to acquire Aimmune Therapeutics, Inc., Nestlé has finally thrown in the towel on the therapy at the centre of that purchase, the peanut allergy treatment Palforzia.

Following a strategic review, the food and beverages giant confirmed that it had divested Palforzia (Arachis hypogaea allergen powder) to Swiss allergy specialist Stallergenes Greer Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.